30 October 2015 - CADTH has received notice of pending submissions from Shire for teduglutide (Revestive) for short bowel syndrome and from Vertex for lumacaftor with ivacaftor (Orkambi) for cystic fibrosis.

For more details, go to: https://www.cadth.ca/news/call-for-patient-input-revestive-and-orkambi